BALTIMORE, Nov. 3, 2010 /PRNewswire/ — Champions Biotechnology,
Inc. (OTC Bulletin Board:
CSBR), a company engaged in the development of advanced
preclinical platforms and tumor specific data to enhance the value
of oncology drugs, today received $1.46 million in grants as part
of the Qualifying Therapeutic Discovery Project (“QTDP”). The QTDP
was enacted as part of the Patient Protection and Affordable Care
Act of 2010.
About Champions Biotechnology, Inc. Champions Biotechnology,
Inc. is engaged in the development of advanced preclinical
platforms and predictive tumor specific data to enhance and
accelerate the value of oncology drugs. The Company’s
Preclinical Platform is a novel approach based upon the
implantation of primary human tumors in immune deficient mice
followed by propagation of the resulting xenografts (Biomerk
Tumorgrafts™) in a manner that preserves the biological
characteristics of the original human tumor. The Company
believes that these Tumorgrafts closely reflect human cancer
biology and their response to drugs is more predictive of clinical
outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to
evaluate drug candidates and to develop a portfolio of novel
therapeutic candidates. The Company also offers its
predictive preclinical platform and tumor specific data to
physicians for personalized patient care and to Companies for
evaluation of oncology drugs and drug candidates in models that
integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical
development tools, accelerating development and valuation of
oncology drugs, and advancing personalized treatment with a goal to
improve the lives of cancer patients globally.
This press release contains “forward-looking statements”
(within the meaning of the Private Sec